Want to see IPSC full AI Analyst Report?
IPSC Stock Chart & Stats
$2.14
-$0.02(-0.95%)
At close: 4:00 PM EDT
$2.14
-$0.02(-0.95%)
Day’s Range― - ―
52-Week Range$0.44 - $3.04
Previous Close$2.08
Volume496.67K
Average Volume (3M)743.66K
Market Cap
$296.96M
Enterprise Value$423.11M
Total Cash (Recent Filing)$119.71M
Total Debt (Recent Filing)$34.63M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Nov 05, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding181,075,320
10 Day Avg. Volume889,317
30 Day Avg. Volume743,663
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.54
Price to Sales (P/S)0.79
P/FCF Ratio-0.82
Enterprise Value/Market Cap1.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.57
Enterprise Value/Ebitda-4.57
Forecast
1Y Price Target
$5.90Price Target Upside175.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CNTY-813 ProgressThe CNTY-813 data address several development hurdles at once: sustained biological activity, reproducible clinical-scale manufacturing, engraftment, and product storage. Together, these findings can improve the program’s readiness for human testing and support a more scalable therapy platform if translated clinically.
Pipeline AdvancementRegulatory alignment and progress toward clinical entry provide tangible milestones beyond laboratory research. Advancing both CNTY-813 and CNTY-308 broadens the potential product base and creates multiple opportunities for clinical validation of Century’s allogeneic cell-therapy approach.
Cash RunwayA projected runway into early 2029 gives Century time to pursue important pipeline milestones without an immediately disclosed financing need. This funding visibility can support continued clinical development and preserves flexibility while the company works toward generating product revenue.
Bears Say
No Current RevenueZero trailing revenue confirms that Century remains dependent on development-stage funding rather than commercial operations. The large net loss indicates that current programs have not yet produced a recurring revenue base, leaving future financial performance tied closely to clinical and regulatory progress.
Heavy Cash BurnSubstantial operating and free-cash-flow losses show that Century is not self-funding its activities. Continued burn will reduce available resources over time and may require additional capital before commercialization, potentially limiting strategic flexibility even with the currently projected runway.
Negative Equity ReturnsSharply negative returns indicate that shareholder capital is currently supporting losses rather than producing earnings. If profitability remains delayed, ongoing equity pressure could persist and future funding needs may increase, making durable value creation dependent on successful development and eventual commercialization.
Century Therapeutics News
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $0.43 and its highest was $3.04 in the past 12 months.
What is Century Therapeutics’s market cap?
Century Therapeutics’s market cap is $296.96M.
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on Aug 12, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.06.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 181,075,320 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went down -4.854%.
Which hedge fund is a major shareholder of Century Therapeutics?
Currently, no hedge funds are holding shares in IPSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Century Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.90 (175.70% Upside)
$5.90 (175.70% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
184.95%
12-Months-Change
Fundamentals
Return on Equity
-52.76%
Trailing 12-Months
Asset Growth
0.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Century Therapeutics
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
IPSC Stock 12 Month Forecast
Average Price Target
$5.90
▲(175.70% Upside)
Technical Analysis
Ownership Overview
3.27% Insiders
3.53% Mutual Funds
0.04% Other Institutional Investors
86.19% Public Companies and
Individual Investors